ATE426617T1 - Therapeutische und diagnostische anti-hsp 70- antikírper - Google Patents

Therapeutische und diagnostische anti-hsp 70- antikírper

Info

Publication number
ATE426617T1
ATE426617T1 AT04803556T AT04803556T ATE426617T1 AT E426617 T1 ATE426617 T1 AT E426617T1 AT 04803556 T AT04803556 T AT 04803556T AT 04803556 T AT04803556 T AT 04803556T AT E426617 T1 ATE426617 T1 AT E426617T1
Authority
AT
Austria
Prior art keywords
antibodies
hsp
therapeutic
cells
diagnostic anti
Prior art date
Application number
AT04803556T
Other languages
English (en)
Inventor
Gabriele Multhoff
Original Assignee
Multimmune Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34639281&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE426617(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Multimmune Gmbh filed Critical Multimmune Gmbh
Application granted granted Critical
Publication of ATE426617T1 publication Critical patent/ATE426617T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT04803556T 2003-12-05 2004-12-06 Therapeutische und diagnostische anti-hsp 70- antikírper ATE426617T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03028144 2003-12-05

Publications (1)

Publication Number Publication Date
ATE426617T1 true ATE426617T1 (de) 2009-04-15

Family

ID=34639281

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04803556T ATE426617T1 (de) 2003-12-05 2004-12-06 Therapeutische und diagnostische anti-hsp 70- antikírper

Country Status (8)

Country Link
US (3) US7700737B2 (de)
EP (2) EP2070947B1 (de)
JP (2) JP4898452B2 (de)
AT (1) ATE426617T1 (de)
CY (2) CY1109125T1 (de)
DE (1) DE602004020266D1 (de)
ES (2) ES2484340T3 (de)
WO (1) WO2005054295A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700737B2 (en) * 2003-12-05 2010-04-20 Multimmune Gmbh Therapeutic and diagnostic anti-Hsp70 antibodies
EP1951281B1 (de) 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Wt1 hla klasse ii-bindungspeptide und diese umfassende zusammensetzungen und verfahren
WO2007120673A2 (en) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
US8540985B2 (en) 2008-06-26 2013-09-24 Orphazyme Aps Use of Hsp70 as a regulator of enzymatic activity
WO2011154908A1 (en) * 2010-06-08 2011-12-15 National University Of Ireland, Galway Manipulation of hsp70 and ire1alpha protein interactions
RU2013125923A (ru) 2010-11-30 2015-01-10 Орфазиме Апс СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70
AU2013207669C1 (en) 2012-01-13 2018-05-31 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
RS61173B1 (sr) 2013-01-15 2021-01-29 Memorial Sloan Kettering Cancer Center Imunogeni wt-1 peptidi i postupci za njihovu upotrebu
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
US10709700B2 (en) 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
BR112017013981A2 (pt) 2015-01-26 2018-01-02 Cellectis receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
WO2016120325A1 (en) * 2015-01-27 2016-08-04 Klinikum Rechts Der Isar Der Technischen Universität München Quantitative assay for heat shock protein 70 (hsp70) protein in body fluids
JP6144447B1 (ja) * 2016-02-02 2017-07-05 エム・テクニック株式会社 微粒子分散液の精密改質方法
EP3442530A1 (de) 2016-04-13 2019-02-20 Orphazyme A/S Hitzeschockproteinen und cholesterinhomöostase
KR20210059796A (ko) 2016-04-29 2021-05-25 오르파짐 에이/에스 글루코세레브로시다제 연관 장애를 치료하기 위한 아리모클로몰
US12053505B2 (en) 2017-08-31 2024-08-06 Multimmune Gmbh Hsp70 based combination therapy
EP4125946A4 (de) * 2020-03-27 2024-04-24 Board of Regents, The University of Texas System Gegen hsp70 gerichtete monoklonale antikörper und therapeutische verwendungen davon
KR20230128462A (ko) 2020-11-19 2023-09-05 제브라 덴마크 에이/에스 아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정
WO2023056361A1 (en) 2021-09-29 2023-04-06 Board Of Regents, The University Of Texas System Anti-hsp70 antibodies and therapeutic uses thereof
WO2024242202A1 (ja) * 2023-05-25 2024-11-28 公立大学法人大阪 抗Ｈｓｐ７０抗体

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
ES2123062T3 (es) 1992-08-21 1999-01-01 Biogen Inc Polipeptidos de transporte derivados de la proteina tat.
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
JP3626187B2 (ja) 1993-06-07 2005-03-02 バイカル インコーポレイテッド 遺伝子治療に適するプラスミド
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
BR9606706A (pt) 1995-10-16 1999-04-06 Unilever Nv Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
ATE473242T1 (de) 1998-05-20 2010-07-15 Immunomedics Inc Therapeutische mittel welche einen bispezifischen anti-hla class ii invariant chain x anti-pathogen antikörper enthalten
EP1284752A4 (de) 2000-04-26 2004-08-18 Elusys Therapeutics Inc Biospezifische moleküle und deren verwendung
ES2326114T3 (es) * 2000-09-13 2009-10-01 Multimmune Gmbh Un peptido de hsp70 estimulador de la actividad de las celulas asesinas naturales (nk) y los usos del mismo.
EP1496888A1 (de) 2002-04-12 2005-01-19 multimmune GmbH Nicht toxische mengen an protein aggregierenden substanzen stimulieren hsp70 expression und fungieren als anti tumor wirkstoffe
EP1695093A1 (de) 2003-12-05 2006-08-30 multimmune GmbH Verbindungen und verfahren zur behandlung und diagnose von neoplastischen und infektiösen krankheiten
US7700737B2 (en) * 2003-12-05 2010-04-20 Multimmune Gmbh Therapeutic and diagnostic anti-Hsp70 antibodies

Also Published As

Publication number Publication date
EP2070947A1 (de) 2009-06-17
JP2008502314A (ja) 2008-01-31
US20120087931A1 (en) 2012-04-12
ES2324538T3 (es) 2009-08-10
JP2012006933A (ja) 2012-01-12
US20070231337A1 (en) 2007-10-04
EP1706423B8 (de) 2009-07-08
WO2005054295A3 (en) 2006-12-28
WO2005054295A8 (en) 2005-08-18
EP1706423A2 (de) 2006-10-04
CY1109125T1 (el) 2014-07-02
ES2484340T3 (es) 2014-08-11
EP1706423B1 (de) 2009-03-25
WO2005054295A2 (en) 2005-06-16
EP2070947B1 (de) 2014-06-11
JP5414750B2 (ja) 2014-02-12
JP4898452B2 (ja) 2012-03-14
US8440188B2 (en) 2013-05-14
US20100143356A1 (en) 2010-06-10
US7700737B2 (en) 2010-04-20
DE602004020266D1 (de) 2009-05-07
CY1116052T1 (el) 2017-02-08

Similar Documents

Publication Publication Date Title
CY1116052T1 (el) Θεραπευτικα και διαγνωστικα αντι-ηsρ70 αντισωματα
CY1111147T1 (el) Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
TNSN05300A1 (en) Treatment with anti-vegf antibodies
ATE422358T1 (de) Kombinationstherapie mittels reovirus und anti- antireovirus antikörpern zur behandlung von ras- vermittelten, proliferativen erkrankungen
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
PT2092938E (pt) Péptidos derivados de survivina e a sua utilização
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
CY2013004I2 (el) Προϊοντα συζευξης auristatin και χρηση αυτων για θεραπεια καρκινου, αυτοανοσης ασθενειας ή μολυσματωδους ασθενειας
CY1106152T1 (el) Νεα ανοσογονα αντι-hiv (ανατοξινες), μεθοδοι παρασκευης και εφαρμογη στην προληψη και στην αγωγη του aids
CY1105818T1 (el) Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
CY1115407T1 (el) Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων
CY1114422T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει αρσενικωδες για τη θεραπευτικη αντιμετωπιση κακοηθειας
WO2003039591A3 (de) Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle
WO2006027693A8 (en) Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis
WO2003080800A3 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
ATE373711T1 (de) Gewebe-spezifische protein 103p2d6, hochexprimiert in verschiedene krebsarten
ATE435284T1 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs
AU2003245858A8 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
CY1108412T1 (el) Συνθεσεις εμβολιου που περιλαμβανουν omp85 πρωτεϊνες απο neisseria gonorrhoea και neisseria miningitidis
ATE527282T1 (de) Tumor assoziierte antigene
DE69803052D1 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt
Singh et al. Unusual Presentation of Glomus Tumor in a Child
AR023380A1 (es) Compuestos para la terapia y el diagnostico de cancer de pulmon y metodos de uso de los mismos
ATE411313T1 (de) Neue makrocyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1706423

Country of ref document: EP